Salmikangas Sami, Böhling Tom, Merikoski Nanna, Jagdeo Joanna, Sampo Mika, Vesterinen Tiina, Sihto Harri
Department of Pathology, University of Helsinki and Helsinki University Hospital, FI-00014 Helsinki, Finland.
Department of Pathology, HUSLAB, HUS Diagnostic Center, University of Helsinki and Helsinki University Hospital, FI-00029 Helsinki, Finland.
Cancers (Basel). 2022 Jun 30;14(13):3212. doi: 10.3390/cancers14133212.
GIST is a rare soft tissue sarcoma, for which KIT and DOG1 are used as highly sensitive diagnostic markers. Other diagnostic markers include CD34, protein kinase C θ, deficiency of succinate dehydrogenase complex subunit B, carbonic anhydrase II, and type I insulin-like growth factor receptor. We investigated the role of TNS2 as a diagnostic biomarker by using immunohistochemistry in 176 GISTs and 521 other sarcomas. All GISTs expressed TNS2, with intermediate or high expression in 71.4% of samples. The majority (89.8%) of other sarcomas were negative for TNS2, and intermediate to strong staining was only seen in 2.9% of samples. Strong TNS2 staining was associated with gastric location (gastric 52.8% vs. non-gastric 7.2%; p < 0.001), absence of metastases (non-metastatic tumors 44.3% vs. metastatic tumors 5.9%; p = 0.004), female sex (female 45.9% vs. male 33.8%; p = 0.029), and tumors of lower risk categories (very low or low 46.9% vs. intermediate 51.7% vs. high 29.0%; p = 0.020). TNS2 expression did not correlate with overall survival or metastasis-free survival. No associations between TNS2 expression and KIT/PDGFRA mutation status, tumor size, mitotic count, or age of the patient were detected. The results provide conclusive evidence for the value of TNS2 as a sensitive and specific diagnostic biomarker for GIST.
胃肠道间质瘤（GIST）是一种罕见的软组织肉瘤，KIT和DOG1被用作高度敏感的诊断标志物。其他诊断标志物包括CD34、蛋白激酶C θ、琥珀酸脱氢酶复合物亚基B缺乏、碳酸酐酶II和I型胰岛素样生长因子受体。我们通过免疫组织化学研究了TNS2在176例GIST和521例其他肉瘤中作为诊断生物标志物的作用。所有GIST均表达TNS2，71.4%的样本呈中度或高表达。大多数（89.8%）其他肉瘤的TNS2呈阴性，仅2.9%的样本可见中度至强染色。TNS2强染色与胃的位置（胃：52.8% vs.非胃：7.2%；p < 0.001）、无转移（非转移性肿瘤：44.3% vs.转移性肿瘤：5.9%；p = 0.004）、女性性别（女性：45.9% vs.男性：33.8%；p = 0.029）以及低风险类别的肿瘤（极低或低风险：46.9% vs.中度风险：51.7% vs.高风险：29.0%；p = 0.020）相关。TNS2表达与总生存期或无转移生存期无关。未检测到TNS2表达与KIT/PDGFRA突变状态、肿瘤大小、有丝分裂计数或患者年龄之间存在关联。这些结果为TNS2作为GIST敏感且特异的诊断生物标志物的价值提供了确凿证据。
